Publié dans Therapies.

THERAPIES - SOMMAIRE MAI JUIN 2023

Le Vol 78 - N°3 - MAI JUIN 2023 est en ligne

Sommaire

Editorials

·Some comments about public perception of drug risk

Gilles Bouvenot, Pierre Le Coz

·Histoire de la pharmacologie–toxicologie à Limoges

History of pharmacology–toxicology in Limoges

Pierre Marquet, Marie-Laure Laroche, Louis Merle, Gérard Lachâtre, au nom de la pharmacologie-toxicologie Limousine

Addictovigilance

·Minors and young adult's hospitalizations after “chimique” consumption in Mayotte Island: Which substances are involved?

Ruben Goncalves, Alexandre Peyré, Nadège Castaing, Thomas Beeken, Sophie Olivier, Patrice Combe, Ghada Miremont-Salamé, Karine Titier, Mathieu Molimard, Amélie Daveluy

Clinical pharmacology

·Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections

Zineb Ghrieb, Maud Salmona, David Michonneau, Charles De Saisset, Souhil Allaoua, Jean-Jacques Kiladjian, Jérôme Le Goff, Anne Bergeron, Lina Benajiba

Clinical research

·Les demandes d’analyses des caractéristiques génétiques par séquençage dans les recherches cliniques : considérations juridiques et éthiques

Requests for genetic characteristics analysis by sequencing in clinical research: Legal and ethical considerations

Bertille Desbrest, Bettina Couderc

Pharmacoepidemiology

·The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control study

Wenpei Liu, Nannan Wang, Jia Zhu, Meiling Zhang, Lihuan Lu, Hongqiu Pan, Xiaomin He, Honggang Yi, Shaowen Tang

Pharmacovigilance

·Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients

Sébastien Gendarme, Jean Pastré, Eliane M. Billaud, Laure Gibault, Romain Guillemain, Stéphane Oudard, Jacques Medioni, Agnès Lillo-Lelouet, Dominique Israël-Biet

·Vaccines and Bell's palsy: A narrative review

Blandine Bertin, Guillaume Grenet, Véronique Pizzoglio-Billaudaz, Marion Lepelley, Marina Atzenhoffer, Thierry Vial

·The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans

Rafael Dal-Ré

·Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort

Manon Pluye, Aurore Gouraud, Magali Herve, Ha Le, Tristan Dagonneau, Stéphane Dalle, Judith Cottin, Michel Cucherat, Marina Atzenhoffer

Therapeutic drug monitoring

·Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study

Sawsan M.A. El-Sheikh, Amera Sh. Metwally, Azza A.A. Galal

Letters to editor

·COVID-19: Global inequality in science

Bakthavachalam Elango

·Immune thrombocytopenia following ChAdOx1 vaccine and positive rechallenge with BNT162b2 vaccine: A case report with pharmacovigilance analysis

Anne Murarasu, Gabriel Bertoliatti-Fontana, Nathalie Massy, Haleh Bagheri, Jean-Marc Treluyer, Alexis Regent, Laurent Chouchana

·Érythème noueux associé au vaccin Tozinaméran : à propos de 2 cas et revue de la littérature

Erythema nodosum associated with Tozinameran vaccine: Report of 2 cases and review of the literatureKhouloud Berrim, Rym Sahnoun, Mohamed Ksentini, Rim Athyemen, Kamilia Ksouda, Hanen Affes, Serria Hammemi, Khaled Zeghal, Lobna Ben Mahmoud

·Hospitalisations après consommation de substances psychoactives pendant la pandémie de COVID-19

Hospitalizations after substance use during the COVID-19 pandemic

Claire Dumoulin, Nathalie Ong, Hanta Ramaroson, Louis Letinier, Ghada Miremont-Salamé, Véronique Gilleron, Amélie Daveluy, Justine Perino

·Case report: Confirming a diagnosis of severe olmesartan-associated enteropathy

Lucien Roulet, Lucia Bedatsova, Laurent Merz, Jules Desmeules, Lila Saiah

Dernière mise à jour le 22 mai 2023.